中国南部地区表观健康人群Lp-PLA2水平分布及其与LDL-C、hs-CRP的相关性分析

doi:10.3969/j.issn.1673-8640.2021.012.006

检验医学 ›› 2021, Vol. 36 ›› Issue (12): 1222-1228.DOI: 10.3969/j.issn.1673-8640.2021.012.006

中国南部地区表观健康人群Lp-PLA2水平分布及其与LDL-C、hs-CRP的相关性分析

赵晶晶¹, 张鹏¹, 周湧², 曹颖平³, 黄之虎⁴, 符生苗⁵, 王玉明⁶, 洪国粦⁷, 沈军⁸, 郑磊¹()

1.南方医科大学南方医院检验医学科,广东广州 510515
2.东莞市第五人民医院检验科,广东东莞 523000
3.福建医科大学附属协和医院检验科,福建福州 350001
4.广西壮族自治区民族医院检验科,广西南宁 530001
5.海南省人民医院检验科,海南海口 570311
6.昆明医科大学附属第二医院检验科,云南昆明 650101
7.厦门大学附属第一医院检验科,福建厦门 350213
8.上海市第一人民医院检验科,上海 200080

收稿日期:2020-11-20 出版日期:2021-12-30 发布日期:2021-12-29
通讯作者: 郑磊
作者简介:郑磊,E-mail： nfyyzl@163.com。
赵晶晶,女,1991年生,硕士,技师,主要从事临床生化检验及动脉粥样硬化机制研究;
张鹏,男,1981年生,博士,主治医师,主要从事临床生化检验工作。第一联系人：
赵晶晶与张鹏对本研究具有同等贡献,并列为第一作者。

A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China

ZHAO Jingjing¹, ZHANG Peng¹, ZHOU Yong², CAO Yingping³, HUANG Zhihu⁴, FU Shengmiao⁵, WANG Yuming⁶, HONG Guolin⁷, SHEN Jun⁸, ZHENG Lei¹()

1. Department of Clinical Laboratory,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,China
2. Department of Clinical Laboratory,Dongguan Fifth People's Hospital,Dongguan 523000,Guangdong,China
3. Department of Clinical Laboratory,Union Hospital Affiliated to Fujian Medical University,Fuzhou 350001,Fujian,China
4. Department of Clinical Laboratory,Guangxi Zhuang Autonomous Region People's Hospital,Nanning 530001,Guangxi,China
5. Department of Clinical Laboratory,Hainan Provincial People's Hospital,Haikou 570311,Hainan,China
6. Department of Clinical Laboratory,the Second Affiliated Hospital of Kunming Medical University,Kunming 650101,Yunnan,China
7. Department of Clinical Laboratory,the First Affiliated Hospital of Xiamen University,Xiamen 350213,Fujian,China
8. Department of Clinical Laboratory,Shanghai General Hospital,Shanghai 200080,China

Received:2020-11-20 Online:2021-12-30 Published:2021-12-29
Contact: ZHENG Lei

摘要/Abstract

摘要：

目的探讨中国南部地区表观健康人群脂蛋白相关磷脂酶A2（Lp-PLA2）水平分布及其与低密度脂蛋白胆固醇（LDL-C）、高敏C反应蛋白（hs-CRP）的相关性。方法选取中国南部地区8家三级甲等医院健康体检者2 318名,检测血清Lp-PLA2及血脂[总胆固醇（TC）、三酰甘油（TG）、LDL-C、高密度脂蛋白胆固醇（HDL-C）]、hs-CRP水平,将所有对象按性别和年龄（<50岁、50~59岁、60~69岁、70~79岁、≥80岁）分别分组。采用Pearson相关分析或Spearman相关分析评估各项目之间的相关性。结果中国南部地区2 318名表观健康者血清Lp-PLA2总体水平为（145.84±43.96）ng/mL,参考区间上限为217.93 ng/mL。女性血清Lp-PLA2水平低于男性（P<0.05）。<50岁组血清Lp-PLA2水平低于50~59岁组、60~69岁组及70~79岁组（P<0.05）,与≥80岁组差异无统计学意义（P>0.05）;50~59岁组、60~69岁组及70~79岁组之间血清Lp-PLA2水平差异均无统计学意义（P>0.05）。8家医院中,福建医科大学附属协和医院的血清Lp-PLA2检测结果最低,海南省人民医院的检测结果最高,与其他医院比较,差异均有统计学意义（P<0.05）。相关分析结果显示,Lp-PLA2与LDL-C呈正相关（r=0.163,P<0.05）,与TC、TG、HDL-C和hs-CRP均无相关性（r值分别为-0.028、0.000、0.001、0.088,P>0.05）。结论初步建立了中国南部地区表观健康人群血清Lp-PLA2的参考区间。

关键词: 脂蛋白相关磷脂酶A2, 低密度脂蛋白胆固醇, 高敏C反应蛋白

Abstract:

Objective To investigate the distribution of lipoprotein-associated phospholipase A2（Lp-PLA2） levels in southern China,and to evaluate the relationship between Lp-PLA2 and low-density lipoprotein cholesterol（LDL-C）,high-sensitivity C-reactive protein（hs-CRP）. Methods A total of 2 318 serum samples were collected from 8 Grade 3 Class A hospitals in southern China. Lp-PLA2,blood lipids [total cholesterol（TC）,triglyceride（TG） and high-density lipoprotein cholesterol（HDL-C）] and hs-CRP levels were determined. All the subjects were classified according to sex and ages（<50 years old,50-59 years old,60-69 years old,70-79 years old and ≥80 years old）. Pearson or Spearman correlation analysis was performed to evaluate the correlations between the items. Results The Lp-PLA2 level of 2 318 healthy subjects in southern China was（145.84±43.96） ng/mL,and the upper limit of reference interval was 217.93 ng/mL. The level of serum Lp-PLA2 in females was lower than that in maless（P<0.05）. The level of serum Lp-PLA2 in <50 years old group was lower than those in 50-59,60-69 and 70-79 years old groups（P<0.05）,and there was no statistical significance compared with that in ≥80 years old group（P>0.05）. There was no statistical significance in serum Lp-PLA2 levels among 50-59,60-69 and 70-79 years old groups（P>0.05）. Among the 8 hospitals,the level of Lp-PLA2 in the Union Hospital Affiliated to Fujian Medical University was the lowest,while the level of Lp-PLA2 in Hainan Provincial People's Hospital was the highest,and there was statistical significance compared with the other hospitals（P<0.05）. Lp-PLA2 was positively correlated with LDL-C（r=0.163,P<0.05）,and there was no correlation with TC,TG,HDL-C and hs-CRP（r values were -0.028,0.000,0.001 and 0.088,P>0.05,respectively）. Conclusions The reference interval of Lp-PLA2 in healthy subjects in southern China has been established preliminarily.

Key words: Lipoprotein-associated phospholipase A2, Low-density lipoprotein cholesterol, High-sensitivity C-reactive protein

中图分类号:

Q556

赵晶晶, 张鹏, 周湧, 曹颖平, 黄之虎, 符生苗, 王玉明, 洪国粦, 沈军, 郑磊. 中国南部地区表观健康人群Lp-PLA2水平分布及其与LDL-C、hs-CRP的相关性分析[J]. 检验医学, 2021, 36(12): 1222-1228.

ZHAO Jingjing, ZHANG Peng, ZHOU Yong, CAO Yingping, HUANG Zhihu, FU Shengmiao, WANG Yuming, HONG Guolin, SHEN Jun, ZHENG Lei. A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China[J]. Laboratory Medicine, 2021, 36(12): 1222-1228.

图/表 5

参考文献 31

[1]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[2]	YAMAURA S, SAKASEGAWA S I, KOGUMA E, et al. Novel enzymatic method for assaying Lp-PLA₂ in serum[J]. Clin Chim Acta, 2018, 481:184-188. DOI URL
[3]	WINKLER K, WINKELMANN B R, SCHARNAGL H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study[J]. Circulation, 2005, 111(8):980-987. DOI URL
[4]	SORRIENTO D, IACCARINO G. Inflammation and cardiovascular diseases:the most recent findings[J]. Int J Mol Sci, 2019, 20(16):3879. DOI URL
[5]	WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019, 124(2):315-327. DOI URL
[6]	PACKARD C J, O'REILLY D S,CASLAKE M J,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group[J]. N Engl J Med, 2000, 343(16):1148-1155. DOI URL
[7]	ELKIND M S, TAI W, COATES K, et al. High-sensitivity C-reactive protein,lipoprotein-associated phospholipase A2,and outcome after ischemic stroke[J]. Arch Intern Med, 2006, 166(19):2073-2080. DOI URL
[8]	COLLEY K J, WOLFERT R L, COBBLE M E. Lipoprotein associated phospholipase A(2):role in atherosclerosis and utility as a biomarker for cardiovascular risk[J]. EPMA J, 2011, 2(1):27-38. DOI URL
[9]	CAI A, LI G, CHEN J, et al. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases:a cross-sectional study of Chinese population[J]. BMC Cardiovasc Disord, 2015, 15:14. DOI URL
[10]	GREENLAND P, ALPERT J S, BELLER G A, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2010, 56(25):e50-e103. DOI URL
[11]	PERK J, DE BACKER G, GOHLKE H, et al. European Guidelines on cardiovascular disease prevention in clinical practice(version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of nine societies and by invited experts)[J]. Eur Heart J, 2012, 33(13):1635-1701. DOI URL
[12]	Clinical and Laboratory Standards Institute. Defining,establishing,and verifying reference intervals in the clinical laboratory[S]. C28-A3,CLSI, 2008.
[13]	中华人民共和国国家卫生健康委员会. WS/T 404.4—2018 临床常用生化检验项目参考区间. 第4部分:血清总胆红素、直接胆红素[S]. 2018.
[14]	尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015.
[15]	中华人民共和国卫生部. WS/T 402—2012 临床实验室检验项目参考区间的制定[S]. 2012.
[16]	LEE K K, FORTMANN S P, VARADY A, et al. Racial variation in lipoprotein-associated phospholipase A₂ in older adults[J]. BMC Cardiovasc Disord, 2011, 11:38. DOI URL
[17]	蔺亚晖, 龚美亮, 张鹏, 等. 中国50岁以上表观健康人群多中心外周血脂蛋白相关磷脂酶A2质量浓度参考区间研究[J]. 中华检验医学杂志, 2021, 44(1):32-38.
[18]	丰睿捷, 胡晓晨, 赵莉芳, 等. 表观健康人群血清脂蛋白相关磷脂酶A2参考区间的建立[J]. 检验医学, 2017, 32(6):495-499.
[19]	廖琳, 胡敏, 陈若虹, 等. 长沙地区体检健康成年人血清脂蛋白相关磷脂酶A2活性参考区间的建立[J]. 临床检验杂志, 2018, 36(6):422-425.
[20]	毋小玉, 崔发财, 郑培明, 等. 采用连续监测法建立郑州地区健康成年人血清脂蛋白相关磷脂酶A2活性参考区间[J]. 实验与检验医学, 2021, 39(1):202-205.
[21]	中国老年学学会心脑血管病专业委员会, 中国医师协会检验医师分会心脑血管病专家委员会. 脂蛋白相关磷脂酶A2临床应用专家建议[J]. 中华心血管病杂志, 2015, 43(10):843-847.
[22]	WASSERTHEIL-SMOLLER S, KOOPERBERG C, MCGINN A P, et al. Lipoprotein-associated phospholipase A2,hormone use,and the risk of ischemic stroke in postmenopausal women[J]. Hypertension, 2008, 51(4):1115-1122. DOI URL
[23]	JIANG W W, NIU J D, QI M J, et al. Diagnostic value of combined detection of different indicators for type 2 diabetes mellitus combined with atherosclerotic disease[J]. Zhonghua Yi Xue Za Zhi, 2021, 101(31):2448-2453.
[24]	SOFOGIANNI A, ALKAGIET S, TZIOMALOS K. Lipoprotein-associated phospholipase A2 and coronary Heart Disease[J]. Curr Pharm Des, 2018, 24(3):291-296. DOI URL
[25]	RAVNSKOV U, DE LORGERIL M, DIAMOND D M, et al. LDL-C does not cause cardiovascular disease:a comprehensive review of the current literature[J]. Expert Rev Clin Pharmacol, 2018, 11(10):959-970. DOI URL
[26]	ALBERT M A, GLYNN R J, WOLFERT R L, et al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels[J]. Atherosclerosis, 2005, 182(1):193-198. DOI URL
[27]	RIDKER P M, MACFADYEN J G, WOLFERT R L, et al. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy:an analysis from the JUPITER trial[J]. Clin Chem, 2012, 58(5):877-886. DOI URL
[28]	BLAKE G J, DADA N, FOX J C, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women[J]. J Am Coll Cardiol, 2001, 38(5):1302-1306. DOI URL
[29]	EISAF M, TSELEPIS A D. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis[J]. Biochem Pharmacol, 2003, 66(11):2069-2073. DOI URL
[30]	ROGER V L, GO A S, LLOYD-JONES D M, et al. Heart disease and stroke statistics-2011 update:a report from the American Heart Association[J]. Circulation, 2011, 123(4):e18-e209.
[31]	YANG S, HUANG S, DANIELS L B, et al. NT-proBNP,race and endothelial function in the Multi-Ethnic Study of Atherosclerosis[J]. Heart, 2019, 105(20):1590-1596. DOI URL

组别	例数	Lp-PLA2	95%可信区间
<50岁组	167	133.00±42.56	126.50~139.51
50~59岁组	1 076	147.07±44.05^*	144.43~149.70
60~69岁组	636	147.23±43.13^*	143.87~150.59
70~79岁组	326	147.65±45.15^*	142.73~152.57
≥80岁组	113	140.10±43.56	131.98~148.22

组别	例数	Lp-PLA2	95%可信区间
<50岁组	167	133.00±42.56	126.50~139.51
50~59岁组	1 076	147.07±44.05^*	144.43~149.70
60~69岁组	636	147.23±43.13^*	143.87~150.59
70~79岁组	326	147.65±45.15^*	142.73~152.57
≥80岁组	113	140.10±43.56	131.98~148.22

组别	例数	Lp-PLA2	95%可信区间
男性
<50岁组	78	141.16±42.48^#△	131.58~150.73
50~59岁组	508	155.17±45.29^*□	151.22~159.12
60~69岁组	355	153.71±43.01^*□	149.22~158.20
70~79岁组	199	149.52±46.92	142.96~156.08
≥80岁组	65	140.95±44.26^#△	129.98~151.92
女性
<50岁组	89	125.86±41.56^#△▲	117.10~134.61
50~59岁组	568	139.82±41.64^*	136.39~143.25
60~69岁组	281	139.04±41.94^*	134.12~143.97
70~79岁组	127	144.73±42.24^*	137.31~152.15
≥80岁组	48	138.95±43.04	126.45~151.45

组别	例数	Lp-PLA2	95%可信区间
男性
<50岁组	78	141.16±42.48^#△	131.58~150.73
50~59岁组	508	155.17±45.29^*□	151.22~159.12
60~69岁组	355	153.71±43.01^*□	149.22~158.20
70~79岁组	199	149.52±46.92	142.96~156.08
≥80岁组	65	140.95±44.26^#△	129.98~151.92
女性
<50岁组	89	125.86±41.56^#△▲	117.10~134.61
50~59岁组	568	139.82±41.64^*	136.39~143.25
60~69岁组	281	139.04±41.94^*	134.12~143.97
70~79岁组	127	144.73±42.24^*	137.31~152.15
≥80岁组	48	138.95±43.04	126.45~151.45

医院名称	例数	性别		年龄/岁	Lp-PLA2/（ng/mL）
医院名称	例数	男/例	女/例	年龄/岁	Lp-PLA2/（ng/mL）
东莞市第五人民医院	245	118	127	58.71±8.61	149.20±47.00^*#
福建医科大学附属协和医院	215	105	110	40.71±12.46	135.21±44.03^#
广西壮族自治区民族医院	227	101	126	63.40±9.56	141.67±41.91^*#
海南省人民医院	251	127	124	60.22±9.43	157.67±41.44
昆明医科大学附属第二医院	546	275	271	62.54±9.64	147.50±44.05^*#
南方医科大学南方医院	363	135	228	60.73±9.10	142.88±45.18^*#
厦门大学附属第一医院	160	85	75	61.20±8.67	150.24±45.01^*#
上海市第一人民医院	311	166	145	62.50±9.60	142.32±40.22^*#
合计	2 318	1 112	1 206	59.56±11.45	145.84±43.96^*#

中国南部地区表观健康人群Lp-PLA2水平分布及其与LDL-C、hs-CRP的相关性分析

A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 31

相关文章 15

编辑推荐

Metrics

性别	例数	Lp-PLA2	参考区间上限
男性	1 205	152.13±44.83	225.65
女性	1 113	139.03±41.98	207.88
合计	2 318	145.84±43.96	217.93

[1]	伏艺, 杨雪松, 金立钢, 翟红礼, 金小玲. sd-LDL-C与ACS患者远期不良心血管事件发生的相关性[J]. 检验医学, 2023, 38(9): 878-883.
[2]	马建国, 李洪春. 冠心病患者血脂水平与心功能指标的相关性[J]. 检验医学, 2023, 38(7): 659-664.
[3]	苏珍珍, 邹继华, 王惠民, 徐炜烽, 丁方, 张晶梅, 王占科. 血清LDL-P与LDL-C检测结果一致性分析[J]. 检验医学, 2023, 38(2): 148-152.
[4]	邢宝宝, 曹银芳. sd-LDL-C/LDL-C比值对AMI患者介入治疗后支架内再狭窄的预测价值[J]. 检验医学, 2023, 38(10): 941-945.
[5]	张一帆, 李长平, 张莉莉, 陈忠. 不同年龄心血管疾病患者血浆半乳凝集素3与低密度脂蛋白胆固醇的相关性[J]. 检验医学, 2023, 38(1): 8-13.
[6]	柴凤霞, 唐丽华, 王磊. Lp-PLA2和hs-CRP在动脉粥样硬化评估中的应用[J]. 检验医学, 2022, 37(8): 798-799.
[7]	李东秀, 黄健. 血清sICAM-1和hs-CRP水平在儿童急性病毒性下呼吸道感染病情监测中的意义[J]. 检验医学, 2022, 37(3): 226-229.
[8]	胡金雅, 穆斌, 孟祥安. 轻度认知功能障碍患者Aβ1-42、Tau 蛋白、Lp-PLA2水平变化及其与脑电图的关系[J]. 检验医学, 2022, 37(11): 1044-1048.
[9]	沈盈, 徐晓萍, 张乐乐, 杜勇平, 孟超. 非空腹血液样本LDL-C检测的临床应用价值[J]. 检验医学, 2022, 37(11): 1049-1056.
[10]	满春露, 杨青松. 血清脂蛋白相关磷脂酶A2和超氧化物歧化酶在脑小血管病患者轻度认知障碍中的临床价值[J]. 检验医学, 2022, 37(10): 939-943.
[11]	彭琰君, 韩雪晶, 唐红霞, 陈俊萌, 贾克刚. 核磁共振波谱法与传统生化检测方法血脂检测结果相关性分析[J]. 检验医学, 2021, 36(7): 733-737.
[12]	李静, 全晖, 曾志荣, 韦祎. 成都地区表观健康者小而密低密度脂蛋白胆固醇参考区间建立[J]. 检验医学, 2021, 36(6): 609-614.
[13]	汪倩, 朱诗瑶, 陆笛, 朱锟, 吴炯, 全佳丽. 动脉粥样硬化性心血管疾病风险标志物研究进展[J]. 检验医学, 2021, 36(4): 447-452.
[14]	朱勇琳, 王绿娅, 鄢盛恺. 低密度脂蛋白受体基因突变及功能检测和临床应用进展[J]. 检验医学, 2021, 36(12): 1287-1291.
[15]	梁涛, 刘凤, 张德太, 王琳, 胡丽华. 武汉地区表观健康人群脂蛋白相关磷脂酶A2水平调查[J]. 检验医学, 2020, 35(9): 889-894.